Article Highlights Importance of Methods for Early Detection and Diagnosis of Disease
Power3 Medical Products, Inc. (OTCBB: PWRM, https://www.power3medical.com), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, was featured in the December issue of Popular Science, the world’s largest science and technology magazine. To view the article, visit the following links: http://www.popsci.com/popsci/science/871ab15144e56110vgnvcm1000004 eecbccdrcrd.html?s_prop16=RSS:home(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)or http://ppx.popsci.com/security/view.php?symbol=BCTEST
The article, titled “Diagnosis 2.0: A new blood test promises to spot cancer and Alzheimer’s long before you get sick,” highlights Power3’s BC-SeraPro™ blood serum diagnostic test, which the company expects to release early next year in the U.S. (Power3 has launched the test in the twelve Middle Eastern countries through a distribution agreement with Financial Advisory House.) The author writes the test is the “first diagnostic to emerge from a fast-growing field known as proteomics that looks for telltale proteins in a person’s blood.” The article speaks to Power3’s ability to detect when the disease is active before physical symptoms appear in the body. This technology allows a physician to detect the disease much earlier and through a less invasive method than mammogram or biopsy. The article notes Power3’s test will be used as a supplement to existing tests, providing an additional method for early detection of disease.
“We are delighted to be recognized in Popular Science’s ‘100 Best Innovations of the Year’ edition,” said Steven Rash, Chief Executive Officer of Power3. “We believe our blood serum diagnostic is of critical importance at a time when new methods of early detection are widely needed around the world.”
Popular Science has a circulation of 1.3 million and 6.8 million monthly readers.
About Popular Science
Founded in 1872, Popular Science is the world’s largest science and technology magazine; with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward what’s new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products, Inc.
Steven B. Rash, 281-466-1600
srash@power3medical.com
or
The Investor Relations Group
Investor Relations:
Adam Holdsworth / Rachel Colgate /
Erica Ruderman, 212-825-3210
or
Media Relations:
Susan Morgenbesser / Janet Vasquez, 212-825-3210